These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 29772196)
1. Ataxin-2 Is Droppin' Some Knowledge. Becker LA; Gitler AD Neuron; 2018 May; 98(4):673-675. PubMed ID: 29772196 [TBL] [Abstract][Full Text] [Related]
2. RNP-Granule Assembly via Ataxin-2 Disordered Domains Is Required for Long-Term Memory and Neurodegeneration. Bakthavachalu B; Huelsmeier J; Sudhakaran IP; Hillebrand J; Singh A; Petrauskas A; Thiagarajan D; Sankaranarayanan M; Mizoue L; Anderson EN; Pandey UB; Ross E; VijayRaghavan K; Parker R; Ramaswami M Neuron; 2018 May; 98(4):754-766.e4. PubMed ID: 29772202 [TBL] [Abstract][Full Text] [Related]
3. Structured and disordered regions of Ataxin-2 contribute differently to the specificity and efficiency of mRNP granule formation. Petrauskas A; Fortunati DL; Kandi AR; Pothapragada SS; Agrawal K; Singh A; Huelsmeier J; Hillebrand J; Brown G; Chaturvedi D; Lee J; Lim C; Auburger G; VijayRaghavan K; Ramaswami M; Bakthavachalu B PLoS Genet; 2024 May; 20(5):e1011251. PubMed ID: 38768217 [TBL] [Abstract][Full Text] [Related]
4. A C-terminal ataxin-2 disordered region promotes Huntingtin protein aggregation and neurodegeneration in Drosophila models of Huntington's disease. Huelsmeier J; Walker E; Bakthavachalu B; Ramaswami M G3 (Bethesda); 2021 Dec; 11(12):. PubMed ID: 34718534 [TBL] [Abstract][Full Text] [Related]
5. Antagonistic roles for Ataxin-2 structured and disordered domains in RNP condensation. Singh A; Hulsmeier J; Kandi AR; Pothapragada SS; Hillebrand J; Petrauskas A; Agrawal K; Rt K; Thiagarajan D; Jayaprakashappa D; VijayRaghavan K; Ramaswami M; Bakthavachalu B Elife; 2021 Mar; 10():. PubMed ID: 33689682 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Becker LA; Huang B; Bieri G; Ma R; Knowles DA; Jafar-Nejad P; Messing J; Kim HJ; Soriano A; Auburger G; Pulst SM; Taylor JP; Rigo F; Gitler AD Nature; 2017 Apr; 544(7650):367-371. PubMed ID: 28405022 [TBL] [Abstract][Full Text] [Related]
7. Motor neurone disease/amyotrophic lateral sclerosis associated with intermediate-length CAG repeat expansions in Ataxin-2 does not have 1C2-positive polyglutamine inclusions. Highley JR; Lorente Pons A; Cooper-Knock J; Wharton SB; Ince PG; Shaw PJ; Wood J; Kirby J Neuropathol Appl Neurobiol; 2016 Jun; 42(4):377-89. PubMed ID: 26095883 [TBL] [Abstract][Full Text] [Related]
8. Taking a risk: a therapeutic focus on ataxin-2 in amyotrophic lateral sclerosis? van den Heuvel DM; Harschnitz O; van den Berg LH; Pasterkamp RJ Trends Mol Med; 2014 Jan; 20(1):25-35. PubMed ID: 24140266 [TBL] [Abstract][Full Text] [Related]
9. Pur-alpha functionally interacts with FUS carrying ALS-associated mutations. Di Salvio M; Piccinni V; Gerbino V; Mantoni F; Camerini S; Lenzi J; Rosa A; Chellini L; Loreni F; Carrì MT; Bozzoni I; Cozzolino M; Cestra G Cell Death Dis; 2015 Oct; 6(10):e1943. PubMed ID: 26492376 [TBL] [Abstract][Full Text] [Related]
10. Toxicity of pathogenic ataxin-2 in Drosophila shows dependence on a pure CAG repeat sequence. McGurk L; Rifai OM; Shcherbakova O; Perlegos AE; Byrns CN; Carranza FR; Zhou HW; Kim HJ; Zhu Y; Bonini NM Hum Mol Genet; 2021 Sep; 30(19):1797-1810. PubMed ID: 34077532 [TBL] [Abstract][Full Text] [Related]
11. Futsch/MAP1B mRNA is a translational target of TDP-43 and is neuroprotective in a Drosophila model of amyotrophic lateral sclerosis. Coyne AN; Siddegowda BB; Estes PS; Johannesmeyer J; Kovalik T; Daniel SG; Pearson A; Bowser R; Zarnescu DC J Neurosci; 2014 Nov; 34(48):15962-74. PubMed ID: 25429138 [TBL] [Abstract][Full Text] [Related]